Notice of results and shareholder update

RNS Number : 1000L

Allergy Therapeutics PLC

30 August 2012

 



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Notice of results and shareholder update

Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its Preliminary Results for the year ended 30 June 2012 on Monday 17 September 2012.

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2012 on the 30 August 2012. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 31 March 2012

	£ '000
Total Non-Current Assets	15,085
Total Current Assets	17,207
Total Current Liabilities	(19,027)
Total Non-Current Liabilities	(4,316)
Total Equity	8,949

Consolidated Income Statement for the 6 months ended 31 March 2012

	£'000
Revenue	27,595
Profit after tax for the period	6,777

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2011.

-Ends-

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
FTI Consulting	[phone]
Simon Conway/ Susan Stuart

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

MSCPMMMTMBBJBJT